Jan Reckweg
Clinical Researcher and Psychopharmacologist
Data updated
Research Footprint
Jan Reckweg appears in 16 tracked papers (2020–2026), most studied alongside Ayahuasca, Psilocybin and 5-MeO-DMT, across Neuroimaging & Brain Measures, Depressive Disorders and Healthy Volunteers.
Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).
Frequent co-authors: Johannes Ramaekers, Nathalie Mason and Stefan Toennes.
Background & Research
Jan Reckweg is a clinical researcher and psychopharmacologist whose work focuses on the clinical pharmacology, safety profiling and experiential measurement of contemporary and classical psychedelics. He has co‑authored multiple phase 1 and phase 1/2 studies evaluating a vapourised 5‑methoxy‑N,N‑dimethyltryptamine formulation (GH001) in both healthy volunteers and patients with treatment‑resistant depression, including dose‑ranging safety and psychoactive‑effect characterisations and a phase 1/2 efficacy assessment. Reckweg has also contributed to comparative acute‑effects studies (for example 2C‑B versus psilocybin), investigations of structural brain differences associated with repeated ayahuasca use, and the development and evaluation of rapid assessment tools such as a peak‑experience scale for 5‑MeO‑DMT.
Key Impact
Notable for leading and co‑authoring early‑phase clinical investigations of short‑acting tryptamines (notably vaporised 5‑MeO‑DMT/GH001), and for contributions to safety, psychometric and neuroimaging research in contemporary psychedelic science.
Collaboration Network
23 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Jan Reckweg is associated with.